Precigen, Inc.
PGEN US74017N1054
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Kindler Jeffrey B O |
3.38 USD |
106,837 Sold |
361,109 USD |
29/09/2025 | 30/09/2025 |
| Kirk Randal J O |
3.41 USD |
1,809,667 Sold |
6,170,964 USD |
30/09/2025 | 30/09/2025 |
| Tennant Phil CCO |
3.58 USD |
6,000 Bought |
21,480 USD |
29/09/2025 | 29/09/2025 |
| Kindler Jeffrey B O |
3.60 USD |
67,523 Sold |
243,083 USD |
29/09/2025 | 29/09/2025 |
| Thomasian Harry Jr. CFO |
3.42 USD |
2,932 Bought |
10,027 USD |
25/09/2025 | 26/09/2025 |
| Shah Rutul R COO |
3.40 USD |
2,000 Bought |
6,800 USD |
26/09/2025 | 26/09/2025 |
| Thomasian Harry Jr. CFO |
3.62 USD |
8,284 Bought |
29,988 USD |
25/09/2025 | 25/09/2025 |
| Kirk Randal J O |
3.68 USD |
3,596,892 Sold |
13,236,563 USD |
17/09/2025 | 19/09/2025 |
| Kirk Randal J O |
3.86 USD |
1,403,360 Sold |
5,416,970 USD |
17/09/2025 | 18/09/2025 |
| Agee Nancy H O |
4.60 USD |
15,000 Bought |
69,000 USD |
04/09/2025 | 04/09/2025 |